The Foundation against the pulmonary hypertension offers three scholarships to investigate about the disease for a value of € 30,000

-various entities have worked to promote these items

-the deadline for applications is 28 February

Madrid, February 2011.- the Foundation against pulmonary hypertension (FCHP) has launched three research grantsaimed at promoting the study of this disease in various scientific fields with a maximum duration of one year. In all cases, the last day for applications is 28 February; Thereafter, a jury designated for that purpose will study these proposals.

One of the scholarships, the project Actelion in hypertension pulmonary ”, award of 12,000 euros for a project of original and unpublished research concerned on any aspect related to pulmonary hypertension, proposed by Spanish doctors under 35 years of age.

On the other hand, for the Fellowship of helps the research in the area of the pulmonary Pediatric Arterial hypertension ”, may assist physicians who have completed their period of specialization in cardiology, pneumology, rheumatology and internal medicine, Pediatric Cardiology during the five years prior to the granting of this project; Alternatively, that are in the final year of residence. The amount of this aid is € 12,000.

Finally, BayerHealthCare scholarships are intended for young researchers, so convened two items for stays of one or two months in units of pulmonary hypertension at the national level, with a total strength of 6,000 euros.

According to Enrique Carazo, President of the FCHP, one of the objectives we are pursuing from the Foundation is to promote research about pulmonary hypertension, by what these grants represent a step forward in this regard ”. In addition, Carazo stated that without the collaboration of institutions, businesses and doctors, these grants could be failing to take form, so I want to show my public thanks to all who support us ”.

More information on these scholarships in the FCHP website: www.fchp.es or in the secretaria@fchp.es email address.
On the Pulmonary Arterial hypertension

Pulmonary Arterial hypertension is a rare, without cure disease of unknown origin in the majority of cases. It has a prevalence of 17 cases per million inhabitants. It is caused by high and continuous pressure of the blood in the pulmonary artery. This makes it comes with more difficulty to the lungs and the heart must work more. due to this circumstance, the right side of the heart gradually increases in size, causing its effectiveness will be diminished and consequently increasingly capable of pumping less blood to the rest of the body.

Some of the symptoms of this disease are chest pain, difficulty breathing, excessive tiredness to carry out daily activities, dizziness, swollen ankles, etc. Therefore a person which in simple view is perfectly healthy, can find great difficulties just to climb a ladder, dressing, or even laughing.

Pulmonary hypertension can be idiopathic when it arises without a known cause that produces. On the other hand, the pulmonary hypertension be associated with other diseases such as infections by HIV, connectivopathies, congenital heart disease, drugs and toxic oil syndrome anorectics or medications to reduce appetite.

The present this disease has no cure and the available treatments manage to alleviate her symptoms and quality of life to improve. The expectancy of life for those affected was three years after the diagnosis, what sometimes is compounded by an incorrect initial treatment. However, thanks to scientific advances and progressive knowledge of this disease, some patients live with her more than 20 years, although the main objective of the scientific community and the own FCHP is finding a definitive cure for this disease.